

Interviewer: continuumdemo1@asam.org Assessment Start: 3/18/2022 2:22 PM EST Assessment End: 3/18/2022 4:10 PM EST

ASAM CONTINUUM[™] THE ASAM CRITERIA DECISION ENGINE

NOTE: This report contains an analysis and an initial placement recommendation derived by analyzing questionnaire items using a clinical consensus algorithm. This instrument is not a replacement for individual provider assessment and sound clinical judgment. ASAM and FEi Systems assume no direct or indirect liability for improper care or negative outcomes that may ensue from the use of this instrument. Consider your patient's needs carefully, using this instrument as one of many clinical tools that determine proper care. The criteria may not encompass all levels and types of services which may be available in a changing health care field. Therefore, the criteria may not be wholly relevant to all levels and modalities of care. Interviews conducted by non-medical/non-nursing personnel or via telehealth audio or video will contain more patient self-reported data. Subjective information may alter conclusions or recommendations; therefore, additional clinical assessment may be needed.

Class of Assessment: Intake Interview Was Conducted: In person

ASAM CONTINUUM Assessment

Interviewer: continuumdemo1@asam.org Assessment Start: 3/18/2022 2:22 PM EST Assessment End: 3/18/2022 4:10 PM EST

DIAGNOSTIC FINDINGS

DSM-5 DIAGNOSIS: SUBSTANCE USE DISORDER(S)

Drug	☑ Criteria MetDrugwith severitybased on 11 criteria		△ Imminent Risk Of Withdrawal		
Alcohol	Alcohol Severe		\checkmark		
	9	2 days ago			
Nicotine products	Moderate	1 hour ago	$\overline{\mathbf{V}}$		
	5				

Specific Problematic Substance(s)

Alcohol	(whatever is on sale, usually vodka 1 pt a day)					
	DSM-5 Criteria Met	DSM-5 Criteria Description				
	01	Often taken in larger amounts or longer than intended				
	02	Persistent desire or unsuccessful efforts to cut down or control				
	03	A great deal of time is spent to obtain, use, or recover				
	04	Craving, or a strong desire or urge to use				
	06	Continued use despite persistent or recurrent problems				
	08	Recurrent use in situations in which it is physically hazardous				
	09	Continued use despite causing or worsening a psychological or physical problem				
	10	Tolerance (increased amounts or diminished effect)				
	11	Withdrawal or use to relieve or avoid withdrawal				
Nicotine products	10 days)					
	DSM-5 Criteria Met	DSM-5 Criteria Description				
	02	Persistent desire or unsuccessful efforts to cut down or control				
	04	Craving, or a strong desire or urge to use				
	09	Continued use despite causing or worsening a psychological or physical problem				
	10	Tolerance (increased amounts or diminished effect)				
	11	Withdrawal or use to relieve or avoid withdrawal				

Drug use

Drug	igodoldoldoldoldoldoldoldoldoldoldoldoldol	
None		

Henry endorsed items in The ASAM Criteria instrument that indicate the probability of the above diagnoses and substance use history.

- 1. ASAM CONTINUUM[™] The ASAM Criteria Decision Engine offers optional DSM-5 Substance Use Disorders Diagnoses, if desired, in the Report. DSM-5 Code Numbers and ICD-10 Code Numbers for medical billing purposes are not generated. Contact your EHR resource for these options and any license fees.
- 2. ASAM CONTINUUM[™] considers Substance-Induced Disorder signs and symptoms in calculating their risks in the Level of Care recommendations. This version of the Level of Care Report does not, however, list diagnoses of these conditions.
- 3. **Remission qualifiers** are not implemented in this version of ASAM CONTINUUM[™].
- 4. **Gambling** is not addressed in the ASAM algorithm and it is therefore not currently included in the ASAM CONTINUUM[™] Assessment or Report.
- 5. **Tobacco Use Disorder**: This diagnosis is listed, if present. The current version of ASAM CONTINUUM[™] uses data and tobacco use disorder to calculate interactions across the dimensions of care. Because tobacco use causes fewer social and legal consequences as a result of intoxication than other drugs, historically the levels of care for tobacco use disorder have been less intensive. This version of ASAM CONTINUUM[™] therefore does not report specific level of care recommendations due to tobacco use disorder alone. Treatment is described in The ASAM Criteria textbook (2013 Edition, p. 385).

WITHDRAWAL SCALES

Possible Non-Substance Use Disorder Psychological Conditions

Henry has a history of harm to himself or others, with a relative chronic, historical risk of 1 on a scale of 0 (little or no risk) to 6 (very strong risk). Henry is currently at risk of harming himself or others, with a relative current risk level of 4 on a scale of 0 (little or no risk) to 8 (very strong risk). Henry indicated that the current risk of harm is having a history of psychotic decompensation.

The CIWA-Ar alcohol and sedative withdrawal scale score is 13 on a scale of 0 to 67, indicating moderate withdrawal.

The CINA is not reported in the absence of recent opioid use.

Interviewer: continuumdemo1@asam.org Assessment Start: 3/18/2022 2:22 PM EST Assessment End: 3/18/2022 4:10 PM EST

ADDICTION SEVERITY INDEX COMPOSITE SCORES

The ASI Composite scores rate severity in seven areas of the patient's life. Analysis of his ASI responses revealed the following composite scores:

ASI Composite Scores

Category	Value	
Medical	0.167	ASI Composite Scores
Employment	0.000	
Alcohol	0.482	0.6
Drug	0.060	
Legal	0.000	Nedical provinent Acohol Drub Legal psychiatric
Family and Social	0.350	Netics, chueur Archo, Dune ress, description
Psychiatric	0.114	Nedical Aconol Drub Legal poveriatic



GAF SCORE

<u>Score</u> <u>Range</u>	Patient Score	Description
50 - 41	50	Serious symptoms (e.g., suicidal ideation, severe obsessional rituals, frequent shoplifting) OR any serious impairment in social, occupational, or school functioning (e.g., no friends, unable to keep a job).

CRITICAL ITEMS

The following critical medical/addiction item(s) were noted while completing this assessment:

1. The interviewer was unable to assess whether there is a reemergence of acute symptoms that can be safely addressed only in a medically-monitored setting. Further assessment by a medical professional is recommended.

The following critical psychological/psychiatric item(s) were noted in this assessment:

1. He has attempted suicide during his lifetime.

Interviewer: continuumdemo1@asam.org Assessment Start: 3/18/2022 2:22 PM EST Assessment End: 3/18/2022 4:10 PM EST

DIMENSIONAL ANALYSIS

Dimension 1 - Acute Intoxication and/or Withdrawal Potential

In Dimension 1, the patient's needs regarding withdrawal can be met at: Level 3.7-WM.

Dimension 2 - Biomedical Conditions and Complications

In Dimension 2, the patient's needs regarding biomedical issues can be met at multiple levels, including: Level 0.5, Level 1, Level 2.1, Level 2.5, Level 3.1, Level 3.3, Level 3.5.

Dimension 3 - Emotional, Behavioral or Cognitive Conditions and Complications

In Dimension 3, the patient's needs regarding emotional, behavioral or cognitive conditions and complications can be met at multiple levels, including: Level 2.1-COE, Level 2.5-COE, Level 3.1, Level 3.3, Level 3.3-COE, Level 3.5-COC, Level 3.7-COC.

Dimension 4 - Readiness to Change

In Dimension 4, the patient's needs regarding readiness to change can be met at multiple levels, including: Level 0.5, Level 1, Level 2.1, Level 2.1-COE, Level 2.5, Level 2.5-COE, Level 3.1, Level 3.1-COE, Level 3.5, Level 3.5-COE.

Dimension 5 - Relapse, Continued Use or Continued Problem Potential

In Dimension 5, the patient's needs regarding relapse, continued use or continued problem potential can be met at multiple levels, including: Level 3.1, Level 3.1-COE, Level 3.5, Level 3.5-COE, Level 3.7, Level 3.7-COE.

Dimension 6 - Recovery Environment

In Dimension 6, the patient's needs regarding recovery environment can be met at multiple levels, including: Level 1, Level 2.1, Level 2.5, Level 3.1, Level 3.1-COE, Level 3.5.

Levels of Care			+ WM BIO	Meets Criteria Withdrawal Management Biomedical Conditions				occurring Capable occurring Enhanced				
	Dimension	0.5	1	OTS	2.1	2.5	3.1	3.2	3.3	3.5	3.7	4
	Dimension 1										WM	
	Dimension 2	+	+		+	+	+		+	+		
	Dimension 3				COE	COE	+		+ COE	сос	сос	
	Dimension 4	+	+		+ COE	+ COE	¢ COE			¢ COE		
	Dimension 5						+ COE			+ COE	+ COE	
	Dimension 6		+		+	+	¢ COE			+		

Please refer to Appendix for more details regarding Dimensional Analysis definitions.

ACCESS TO TREATMENT ISSUES

The following items related to access to treatment were noted while completing this assessment:

- 1. Henry has indicated that he is unsteady on his feet, problems with walking or balance, such that he could easily fall or have trouble getting around or using stairs.
- 2. Henry does not have a valid driver's license.
- 3. Henry is unable to locate or safely get to community resources.
- 4. Henry does not have continuous monitoring available on an outpatient basis for the next 8 to 24 hours.
- 5. The clinician deduced from the interview or has information that indicates that Mr W's current behavior may be inconsistent with reliable self-care, safety, or an ability to participate effectively in treatment.
- 6. The patient cannot access services such as assertive community treatment and intensive case management.

FINAL LEVEL OF CARE RECOMMENDATIONS

The patient should be considered for each of the following services. The treatment team should consider his history carefully and provide the patient with the level of care and services that best suit his presentation.

- 1. Henry may require initial treatment in a Level 3.7-WM -- medically monitored inpatient withdrawal management program.
- 2. Henry meets the criteria to be admitted to a Level 3.7 medically monitored intensive inpatient Co-Occurring Enhanced program as he appears to have active co-occurring emotional, behavioral, or cognitive needs and/or risks that may need further evaluation and treatment or treatment revision.

Copyright:

*Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Copyright ©2013 American Psychiatric Association. All Rights Reserved.

Unless authorized in writing by the APA, no part may be reproduced or used in a manner inconsistent with the APA's copyright. This prohibition applies to unauthorized uses or reproductions in any form.

The American Psychiatric Association is not affiliated with and is not endorsing this product.

*Reprinted with permission from the International Classification of Diseases, 10th Edition. World Health Organization. All Rights Reserved.

Unless authorized in writing by the WHO, no part may be reproduced or used in a manner inconsistent with the WHO's copyright. This prohibition applies to unauthorized uses or reproductions in any form.

The World Health Organization is not affiliated with and is not endorsing this product.

Trademark:

*DSM and DSM-5 are registered trademarks of the American Psychiatric Association, and are used with permission herein. Use of these terms is prohibited without permission of the American Psychiatric Association.

Use of this trademark does not constitute endorsement of this product by the American Psychiatric Association.